350 related articles for article (PubMed ID: 24969577)
1. Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
Gudipaty L; Rosenfeld NK; Fuller CS; Gallop R; Schutta MH; Rickels MR
Diabetes Care; 2014 Sep; 37(9):2451-8. PubMed ID: 24969577
[TBL] [Abstract][Full Text] [Related]
2. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
Berg JK; Shenouda SK; Heilmann CR; Gray AL; Holcombe JH
Diabetes Obes Metab; 2011 Nov; 13(11):982-9. PubMed ID: 21615670
[TBL] [Abstract][Full Text] [Related]
3. [New drugs; exenatide and sitagliptin].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
[TBL] [Abstract][Full Text] [Related]
4. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
5. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
7. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
Zhang Y; Chi J; Wang W; Hong J; Gu W; Wang B; Ning G
J Diabetes; 2015 Mar; 7(2):213-21. PubMed ID: 24889731
[TBL] [Abstract][Full Text] [Related]
8. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
[TBL] [Abstract][Full Text] [Related]
9. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
10. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
11. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
[TBL] [Abstract][Full Text] [Related]
12. The design of the liraglutide clinical trial programme.
Nauck MA
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
14. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
[TBL] [Abstract][Full Text] [Related]
15. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
16. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Scheen AJ
Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
[TBL] [Abstract][Full Text] [Related]
17. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
[TBL] [Abstract][Full Text] [Related]
18. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Horton ES; Silberman C; Davis KL; Berria R
Diabetes Care; 2010 Aug; 33(8):1759-65. PubMed ID: 20460445
[TBL] [Abstract][Full Text] [Related]
19. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
[No Abstract] [Full Text] [Related]
20. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Ahrén B
Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
